SMi’s 3rd annual Superbugs & Superdrugs conference returns to New Jersey, on the 12th-13th November 2018. The issue of antibacterial resistance is becoming increasingly prevalent within the world of modern medicine. Difficult-to-treat pathogens create an incredibly real issue within clinical environments; and the problem needs to be addressed with novel treatments and the development of mechanisms which circumvent current therapeutic barriers. To address the ever-growing need of informative and though provoking discussion, in order to address these industry issues, SMi will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

By attending our 3rd annual event, not only would you benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; but you would also receive the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry – from research to commercial providers and regulatory bodies

What our attendees said last year:

"Very interesting range of speakers and topics - really looking forward to the 2018 event!"

"The chairs did a great job of moderating - great discussion"

  • Gain insight into Diagnostic Technologies being used in the field and the futuristic developments which could be implemented.
  • Network with key industry leaders and benefit from though provoking discussions
  • Hear from the main regulatory bodies to advise on guidelines surrounding funding and development
  • Listen to up-and-coming companies, developing novel approaches to circumvent antibacterial resistance
  • Discover new approaches of anti-fungal development

Chief Scientific Officer, Chief operating officer, Chief Medical Officer, Research and Development Manager, Research and Development Director, Research and Development Scientist, Research Assistant, Research Technologist, Professors, Doctors, Research Scientist, PhD student, Research Fellow, Principal Lecturers, Sales Directors, Business Development, Marketing Director, Business Coordinators, Engagement Manager

Achaogen Inc; Amplyx Pharmaceuticals, Inc; Battelle; Centauri Therapeutics; CLINIC; ContraFect; ContraFect Corporation; DeNovaMed Inc; Emergent BioSolutions; Emergent BioSolutions Inc.; Evotec; F2G Ltd; FDA; Forge Therapeutics, Inc.; FUJIFILM Diosynth Biotechnologies; HHS/ASPR/BARDA; Janssen Research & Development, LLC; Laboratoire Biodim; Lovelace Respiratory Research Institute; Macrolide Pharmaceuticals, Inc.; MDLinx; Mdlinx Inc; MedImmune; Merck; Merck & Co.; Microbiotix Inc; Micromyx LLC; Micron Research; Morton Findlay Associates Ltd; Motif BioSciences; N8 Medical LLC; NeoSome Life Sciences, LLC; Nobelex Biotech; Novo AS; Pfizer; Prodigy Biotechnology; Rutgers University; Social & Scientific Systems Inc; Soligenix, Inc.; Teleflex; UNT Health Science Center; UNTHSC, PreClinical Services; Visterra; Weber Shandwick;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

9:10 Discovery and evaluation of inhibitors of intermediary metabolism as novel antibiotics against Gram-negative bacterial pathogens

Brent Cezairliyan

Brent Cezairliyan, Senior Scientist, Octagon Therapeutics

  • Identification of growth conditions that stimulate virulence of the human pathogen Pseudomonas aeruginosa
  • A screening platform to identify novel compounds that inhibit bacterial growth under virulence-stimulating conditions
  • Inhibitors of central metabolism exhibit in vivo activity against P. aeruginosa and Acinetobacter baumannii infections

    9:50 Pathogen-focused drug development: buyer beware

    Ian Friedland

    Ian Friedland, Clinical Consultant, Ex-Chief Medical Officer, Achaogen

  • 10:30 Morning Coffee

    11:00 Overcoming bacterial resistance through a novel mode of action

    Malcolm Thomas

    Malcolm Thomas, CEO, Agile Sciences

  • A new class of 2-aminoamidazole molecules that inhibit bacterial protection mechanisms
  • Disperse and inhibit biofilm formation
  • Lowers effective dose of antibiotic
  • 11:40 VNRX-5133: a highly potent and broad-spectrum inhibitor of both serine and metallo beta-lactamases

    Daniel Pevear

    Daniel Pevear, Sr. Vice President of Biology and Grants Development, Venatorx Pharmaceuticals

  • VNRX-5133 is a boronic acid that exhibits direct, selective and potent inhibitory activity against bacterial serine and metallo-b lactamases
  • VNRX-5133 rescues cefepime activity in strains of ESBL- and carbapenemase-expressing Enterobacteriaceae and Pseudomonas aeruginosa
  • VNRX-5133 is a b-lactamase inhibitor that lacks stand-alone antibacterial activity
  • VNRX-5133 rescues cefepime activity in vivo in multiple animal models of bacterial infection
  • 12:20 Networking Lunch

    13:30 TP-6076: A novel fluorocycline antibiotic with potent activity against carbapenem-resistant Gram (-) organisms

    Joe Newman

    Joe Newman, Senior Director, Head of Biology, Tetraphase Pharmaceuticals

  • TP-6076 is a potent inhibitor of bacterial protein synthesis
  • The activity of TP-6076 is not affected by the common mechanisms of Gram (-) resistance
  • TP-6076 demonstrates potent activity in murine thigh and lung infections
  • 14:10 Immunotherapeutics targeting Pseudomonas aeruginosa acute and persistent infections

    Antonio DiGiandoneico

    Antonio DiGiandoneico, Principal Scientist, MedImmune

  • Introduce novel anti-Pseudomonal mAbs and their mechanisms of action
  • Activity will be discussed in multiple animal models when used in both prophylaxis and treatment indications
  • Activity against biofilms will also be presented
  • Synergy with antibiotic treatment will also be discussed
  • 14:50 Afternoon Tea

    15:20 The state of developments within the anti-fungal space

    Mahmoud Ghannoum

    Mahmoud Ghannoum, Director of Center for Medical Mycology, Case Western Reserve University

  • What is the status of resistance in terms of fungal pathogens?
  • What are the main fungal strains posing the greatest threat to public health?
  • Which are the current anti-fungals currently in use?
  • Where are the gaps in anti-fungal development, which need to be addressed?
  • 16:00 SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp

    Stephen Barat

    Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc

  • Effects of SCY-078 against multi-drug resistant fungal pathogens
  • Results from preclinical PK/PD models for Candida, Aspergillus and Pneumocystis spp
  • Discussion on pharmacokinetic characteristics of SCY-078, including disposition profile
  • Applications in the treatment of life-threatening infections
  • 16:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Anthony Simon Lynch

    Anthony Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen

    9:10 The Microbiome and its impact on the field

    9:50 Supporting antibacterial research and development

    Mark Albrecht

    Mark Albrecht, Project Officer, HHS/ASPR/BARDA

  • What is BARDA and why is it interested in AMR
  • How BARDA partners with industry to stimulate innovation in AMR R&D
  • How CARB-X is refilling the preclinical AMR product pipeline
  • 10:30 Morning Coffee

    11:00 CMC strategies for novel antibiotic drug development

    Evan Hecker

    Evan Hecker, Director of API Development, Spero therapeutics

  • The start to finish process within chemical development – an all-encompassing overview
  • Considerations for oral drug products and parenteral formulations
  • Pre-commercial CMC development, how not to be consumed by CTM deliverables
  • NDA-enabling CMC studies are critical
  • Audit processes of a manufacturing facility – issues and stumbling blocks and obvious red flags
  • 11:40 NIAID funding and resources for development of anti-infectives

    Tina Guina

    Tina Guina, Therapeutics Development Project Officer, NIAID

  • NIAID programmes and funding opportunities in the development of antibacterial therapeutics
  • 12:20 Networking Lunch

    13:30 Update on epidemiology, resistance and treatments of GI related infectious disease

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • Advances in the diagnosis and treatment of Clostridium difficile infections
  • Helicobacter pylori - Latest research and news
  • Drug-resistant intestinal bugs - Salmonella, Shigella, and Yersinia
  • Gut microbiome: a new player in gastrointestinal disease
  • 14:10 Practical clinical diagnostic applications using laser light-scattering: utility, adoption, and opportunities

    Andrew Tomaras

    Andrew Tomaras, VP and Director of Microbiology, BacterioScan Inc.

  • Production of accurate and affordable platform for widespread clinical use
  • Performance of current clinical application for rapid urinary tract infection detection
  • Developmental applications including other direct-from-specimen infection detection and phenotypic antimicrobial susceptibility testing
  • Platform utilization to streamline new antimicrobial clinical trial enrolment and clinical adoption
  • 14:50 Afternoon Tea

    15:20 BACLIB - where lipid-based mass spectrometry phenotyping outperforms current protein-based microbial diagnostics

    Robert Ernst

    Robert Ernst, Professor and Vice Chair Bacterial Pathogenesis, University Of Maryland

  • Microbial membrane glycolipids represent a unique diagnostic target
  • Diagnostic potential directly from clinically relevant material, including blood bottles, urine
  • Applicable for polymicrobial samples from simple or complex samples and reveals patterns of antimicrobial resistance
  • Rapid, microbial identification in less than 60 minutes direct from specimen
  • 16:00 Futuristic outlooks on the non-clinical diagnostic methods which could be implemented into a clinical setting

    16:40 Chairman’s Closing Remarks and Close of Day Two


    Sponsors and Exhibitors

    Official Associations

    Supporting Media Partners


    Renaissance Woodbridge Hotel

    515 US Highway 1 South, Iselin, New Jersey, USA

    Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.


    Sponsors and Exhibitors


    Sponsors and Exhibitors

    SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

    Media Partners


    Supporting Media Partners

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc

    Pharma Journalist

    Supporting Media Partners

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Supporting Media Partners

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

    American Laboratory

    Supporting Media Partners

    For laboratory managers and researchers utilizing analytical chemistry and its applications, seeking knowledge on new technologies, methods, applications, and products, the American Laboratory® publication platform provides comprehensive technology coverage for laboratory professionals at all stages of their careers. Unlike single-channel publications, American Laboratory® is a multidisciplinary resource that engages scientists through print, digital, mobile, multimedia, and social channels to provide practical information and solutions for cutting-edge results. American Laboratory® serves the need of global community of laboratory professionals for communicating relevant technical advances and insights. Globally, American Laboratory® reaches out to subscribers by offering digital distribution plus premium print in North America. Digital communications utilize internet, mobile and social channels.

    American Pharmaceutical Review

    Supporting Media Partners

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Supporting Media Partners

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

    Pharmaceutical Outsourcing

    Supporting Media Partners

    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.

    Infectious Diseases Hub

    Supporting Media Partners

    Infectious Diseases Hub is a free-to-access website open to all researchers, students and anyone else who might have an interest in the many aspects of microbiology and virology. We offer easy access to breaking news, interviews, opinion pieces, peer-reviewed articles and multimedia features, with a strong focus on the rising issue of antimicrobial resistance. Microbiology is such a diverse and exciting area, and with the emergence of new technologies giving us the ability to study complex communities and rapidly sequence whole genomes, there has been something of a ‘revolution’. Keeping on top of such technological advances and the latest emerging diseases is at the heart of Infectious Diseases Hub, and you can take a look at up-to-date essential research and information on the site now.


    Supporting Media Partners

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

    World Pharma News

    Supporting Media Partners

    Technology Networks

    Supporting Media Partners

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    Drug Discovery Today

    Supporting Media Partners

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Supporting Media Partners

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    Official Associations

    Swiss Biotech Association

    Official Associations

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Renaissance Woodbridge Hotel

    515 US Highway 1 South
    Iselin 08830

    Renaissance Woodbridge Hotel

    Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out